As a popular epigenetic target, there is mounting evidence demonstrating that EZH2 can control a wide range of tumor-infiltrating lymphocytes, form an immunosuppressive microenvironment within the tumor, and allow tumor cells to escape the recognition and destruction of the immune system. Here, EZH2 is linked to neoplasm.